

Rec'd PCTO 11 APR 2002

#1

Patent  
Attorney's Docket No. 022701-969

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	
	)	
Gilles LORENTZ et al.	)	
	)	
Application No.: 09/980,785	)	Group Art Unit: Unassigned
(Corresponds to PCT/FR00/01543)	)	
	)	
International Filing Date: 6 JUNE 2000	)	
	)	Examiner: Unassigned
For: USE OF POLYOXYLATED	)	
TERPENE DERIVATIVES FOR	)	
TREATING TEXTILE FIBRES	)	

**LETTER**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants received a Notification of Missing Requirements mailed February 11, 2002 under 35 U.S.C. §371 in the United States Designated/Elected Office.

In particular, the U.S. Patent and Trademark Office has requested an Oath or Declaration from the inventors and they have requested that Applicants Comply with a Nucleotide and/or Amino Acid Sequence Disclosure.

After complete review of the file, Applicants believe that the request to Comply with the Nucleotide and/or Amino Acid Sequence Disclosure was in error. No nucleotide or amino acid sequences are disclosed anywhere in the subject application. The subject application is not directed to the area of biotechnology but rather is directed to a variety of organic chemical compounds.

Accordingly, Applicants will not reply to the Request for a Sequence Listing.

If the Examiner has any questions, a telephone call to Applicants' undersigned representative is respectfully requested.

Respectfully submitted,

BURNS, DOANE, SWICKER & MATHIS, L.L.P.

By: 

Teresa Stanek Rea  
Registration No. 30,427

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

**Date: April 11, 2002**

FORM PCT 1390 (Rev. 9/2001)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S SOCKET NUMBER
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>			022701-969
			U.S. APPLICATION NO. (ARTICLE 37 C.F.R. 1.5)
INTERNATIONAL APPLICATION NO. PCT FR00/01543	INTERNATIONAL FILING DATE 6 JUNE 2000	PRIORITY DATE CLAIMED 7 JUNE 1999	
TITLE OF INVENTION USE OF POLYALKOXYLATED TERPENE DERIVATIVES FOR TREATING TEXTILE FIBERS			
APPLICANT(S) FOR DO/EO/US Gilles LORENTZ et al.			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
1. <input type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371. 2. <input checked="" type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 			
Items 11 to 20 below concern document(s) or information included:			
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information: Letter Regarding Nucleotide and/or Amino Acid Sequence Listing.			



21839

U.S. APPLICATION NO. (Mandatory: see 37 CFR 1.51) <b>09,980,785</b>		INTERNATIONAL APPLICATION NO. <b>PCT/FR00/01543</b>		ATTORNEY'S DOCKET NUMBER <b>022701-969</b>	
--	--	--	--	---	--

21. <input checked="" type="checkbox"/> The following fees are submitted:				<b>CALCULATIONS</b>			
<b>Basic National Fee (37 CFR 1.492(a)(1)-(5)):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and international Search Report not prepared by the EPO or JPO ..... \$1,040.00 (950) International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$890.00 (970) International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$740.00 (953) International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$710.00 (956) International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$100.00 (962)							
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				\$			
Surcharge of <b>\$130.00 (154)</b> for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)). <span style="float: right;">20 <input type="checkbox"/> 30 <input checked="" type="checkbox"/></span>				\$ 130.00			
Claims	Number Filed	Number Extra	Rate				
Total Claims	14 -20 =	0	X\$18.00 (966)	\$			
Independent Claims	1 -3 =	0	X\$84.00 (964)	\$			
Multiple dependent claim(s) (if applicable)			+ \$280.00 (968)	\$			
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$ 130.00			
Reduction for 1:2 for filing by small entity, if applicable (see below).				+			
<b>SUBTOTAL =</b>				\$ 130.00			
Processing fee of <b>\$130.00 (156)</b> for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)). <span style="float: right;">20 <input type="checkbox"/> 30 <input type="checkbox"/></span>				\$			
<b>TOTAL NATIONAL FEE =</b>				\$ 130.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00 (581)</b> per property				+			
<b>TOTAL FEES ENCLOSED =</b>				\$ 130.00			
				<b>Amount to be refunded:</b>		\$	
				<b>charged:</b>		\$	

a. ☐ Small entity status is hereby claimed.

b. ☒ A check in the amount of \$ 130.00 to cover the above fees is enclosed.

c. ☐ Please charge my Deposit Account No. 02-4800 in the amount of \$ \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.

d. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-4800. A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

Norman H. Stepno, Esq.  
BURNS, DOANE, SWECKER & MATHIS, L.L.P.  
P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

SIGNATURE  
**TERESA STANEK REA**  
 NAME  
30,427  
 REGISTRATION NUMBER

APRIL 11, 2002  
 DATE



UNITED STATES PATENT AND TRADEMARK OFFICE

 Commissioner for Patents, Box 401  
 United States Patent and Trademark Office  
 Washington, D.C. 20260  
 www.uspto.gov

U.S. APPLICATION NUMBER NO	FIRST NAMED APPLICANT	ATTY DOCKET NO
09/980,785	Gilles Lorentz	022701-969

INTERNATIONAL APPLICATION NO
PCT/FR00/01543

IA FILING DATE	PRIORITY DATE
06/06/2000	

 21839  
 BURNS DOANE SWECKER & MATHIS L L P  
 POST OFFICE BOX 1404  
 ALEXANDRIA, VA 22313-1404

CONFIRMATION NO. 8783

371 FORMALITIES LETTER




\*OC000000007453340\*

Date Mailed: 02/11/2002

### NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Preliminary Amendments
- Request for Immediate Examination



The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.

**ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.**

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the

 FEB 10 2002  
 02

requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
  - A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
  - APPLICANT MUST PROVIDE:
    - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
    - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
- For Rules Interpretation, call (703) 308-4216
  - To Purchase PatentIn Software, call (703) 306-2600
  - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

BARBARA A CAMPBELL

Telephone: (703) 305-3631

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO	INTERNATIONAL APPLICATION NO	ATTY DOCKET NO
09/980,785	PCT/FR00/01543	022701-969